China Healthcare Weekly (Sep.8)- 9th VBP, Reliable Profit Model of Biotech, Medlive, China's Outlook
⬇ $Medlive Technology(02192)$ - 9th national VBP has begun. We analyzed the impact on companies. 23H1 reports make us realize even with negative policy, China Biotech can still have solid profit model. Medlive's outlook is uncertain
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-sep-8-9th-vbp-reliable-profit-model-of-biotech-medlive-china-s-outlook?utm_source=tiger_community
By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community
On Medlive Technology (02192):- https://www.smartkarma.com/entities/medlive-technology-co-ltd?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
